Healio

FDA approves three new pediatric indications for once-weekly growth hormone injection

The FDA has approved three new pediatric indications for somapacitan-beco, a once-weekly, long-acting growth hormone injection, according to a press release issued by Novo Nordisk.Somapacitan-beco ...
MPR

Sogroya Approval Expanded to Include 3 Additional Pediatric Growth Disorders

Somapacitan, a long-acting human growth hormone analog, was evaluated in growth hormone treatment-naïve, pre-pubertal pediatric patients.
Baylor College of Medicine

BCM, TCH Southwest Pediatric Device Consortium receives FDA grant

The Southwest National Pediatric Device Innovation Consortium (SWPDC), a multi-institutional consortium led by Baylor College of Medicine and Texas Children’s Hospital, has received a Food and Drug ...

FDA approves Novo Nordisk's Sogroya® as the first and only once-weekly, long-acting growth hormone for three additional pediatric indications

Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved three new indications for once-weekly Sogroya® (somapacitan-beco) injection 5 mg, 10 mg, or 15 mg, a ...
Yahoo Finance

Teva Canada Announces Approval of Expanded Indication of [Pr]AJOVY® (fremanezumab solution for subcutaneous injection), the First Anti-CGRP Preventive Treatment for Pediatric ...

Health Canada approves Pr AJOVY® (fremanezumab solution for subcutaneous injection) for the prevention of episodic migraine (fewer than 15 migraine days per month) in pediatric patients aged 6 to 17 ...
Nasdaq

NuGen Medical Devices Receives Health Canada Approval for Its Needle-Free Injection System

First self-administered, needle-free injection system approved by Health Canada gives access to safe, painless, cost-effective, and more sustainable drug delivery for chronic illnesses Toronto, ...